Evaluation of the antimicrobial activity of pyrimidine compound 3-(2-benzyloxy-2-oxoethyl)quinazoline-4(3H)-oh in relation to Klebsiella pneumoniae

The study is devoted to the evaluation of the antimicrobial activity against Klebsiella pneumoniae of the pyrimidine compound 3-(2-Benzyloxy-2-oxoethyl)quinazoline-4(3H)-one under in vivo conditions in a model of generalized infection. The experiment was performed on 40 CBA line mice, which were divided into four groups: Group 1, control animals that received intraperitoneal injection water in an equivalent volume (control I); Group 2, infected animals that received no treatment (control II); Group 3, mice with generalized infection that received ceftriaxone at a dose of 50 mg/kg intraperitoneally for 7 days as treatment; Group 4, infected animals that received the study compound at a dose of 31 mg/kg (1/10 of the molecular weight) for 7 days. Generalized infection was modeled by intraperitoneal injection of Cl. pneumoniae at a dose of 3×106 in a volume of 0.5 ml. In the course of the experiment, animal survival rate was evaluated. After the mice were removed from the experiment, the blood, liver, spleen and lungs were calculated, and the total number of leukocytes, C-reactive protein and procalcitonin were determined. The compound under study was found to increase the survival rate of laboratory animals under conditions of generalized Klebsiella infection, as well as to decrease the insemination index, the total number of leukocytes and the level of markers of generalized infection. Thus, the pyrimidine derivative 3-(2-Benzyloxy-2-oxoethyl)quinazolin-4(3H)-one exhibits antibacterial activity comparable to that of the reference drug — ceftriaxone against Klebsiella pneumoniae under experimental infection.